2008
DOI: 10.1097/01.htr.0000319935.99837.96
|View full text |Cite
|
Sign up to set email alerts
|

The Effectiveness of Donepezil for Cognitive Rehabilitation After Traumatic Brain Injury

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
21
0
5

Year Published

2010
2010
2024
2024

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 42 publications
(26 citation statements)
references
References 20 publications
0
21
0
5
Order By: Relevance
“…This has, in part, been shown to be the case in TBI too. Donepezil a U.S. Food and Drug Administration (FDA) approved anticholinesterase for the treatment of AD has been found to be moderately beneficial in improving memory deficits in several clinical studies and in some, but not all, experimental models of TBI (Taverni et al, 1998; Whelan et al, 2000; Masanic et al, 2001; Balesteros et al, 2008; Fujiki et al, 2008; Shaw et al, 2013; Yu et al, 2015). The N-methyl-d-aspartate antagonist memantine, a further FDA-approved drug for the symptomatic treatment of AD, has similarly been shown to be neuroprotective and to possess anti-lipid peroxidation properties in several preclinical studies involving experimentally induced TBI in rodents (Rao et al, 2001; Ozsuer et al, 2005).…”
Section: Discussionmentioning
confidence: 99%
“…This has, in part, been shown to be the case in TBI too. Donepezil a U.S. Food and Drug Administration (FDA) approved anticholinesterase for the treatment of AD has been found to be moderately beneficial in improving memory deficits in several clinical studies and in some, but not all, experimental models of TBI (Taverni et al, 1998; Whelan et al, 2000; Masanic et al, 2001; Balesteros et al, 2008; Fujiki et al, 2008; Shaw et al, 2013; Yu et al, 2015). The N-methyl-d-aspartate antagonist memantine, a further FDA-approved drug for the symptomatic treatment of AD, has similarly been shown to be neuroprotective and to possess anti-lipid peroxidation properties in several preclinical studies involving experimentally induced TBI in rodents (Rao et al, 2001; Ozsuer et al, 2005).…”
Section: Discussionmentioning
confidence: 99%
“…Altogether these results suggest that the interaction between cholinergic and histaminergic systems is more complex than previously thought and further experiments are required to fully understand its mechanism and physiological implications. Donepezil is currently used in clinics to treat mild cognitive deficits observed in Alzheimer's disease patients (Cummings et al, 2013) and has been proposed for the rehabilitation of cognitive impairments after traumatic brain injuries (Ballesteros et al, 2008).…”
Section: A C C E P T E D Accepted Manuscriptmentioning
confidence: 99%
“…15,16 Among them, acetylcholinesterase inhibitors (AChEIs), which extend the effect of ACh on neurons and restore cholinergic tone, have received the most attention. [12][13][14][15] AChEIs have shown improvement in memory and executive function in TBI patients [17][18][19][20][21][22][23] and mixed results in rodents. 24,25 For example, donepezil, a mixed competitive, reversible, and potent AChEI, exhibits small-to-moderate pro-cognitive effects in humans 23 and in select laboratory conditions.…”
Section: Introductionmentioning
confidence: 99%
“…[12][13][14][15] AChEIs have shown improvement in memory and executive function in TBI patients [17][18][19][20][21][22][23] and mixed results in rodents. 24,25 For example, donepezil, a mixed competitive, reversible, and potent AChEI, exhibits small-to-moderate pro-cognitive effects in humans 23 and in select laboratory conditions. [24][25][26][27][28] In a murine model of cortical impact injury, donepezil was reported to improve spatial learning 24 , however, the effect was modest and the post-hoc statistic did not correct for multiple comparisons, which may have affected the interpretation.…”
Section: Introductionmentioning
confidence: 99%